Quest PharmaTech, Inc. (QPTFF)
0.0133
0.00 (0.00%)
USD |
OTCM |
Feb 20, 16:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 2.249M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 0.00% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 0.1366 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.0433 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 93.18% |
Profile
| Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. It focuses on developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications. The firm is developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target, truncated O-glycans on MUC16. The company was founded in 1996 and is headquartered in Edmonton, Canada. |
| URL | http://www.questpharmatech.com |
| Investor Relations URL | N/A |
| HQ State/Province | Alberta |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Quest PharmaTech, Inc. is a biotechnology company, which develops and commercializes antibody based immunotherapeutic products for cancer. It focuses on developing products utilizing proprietary transdermal delivery technologies with a focus on dermatology and wound healing applications. The firm is developing targeted cancer therapy with its lead product MAb AR9.6, under development for a novel target, truncated O-glycans on MUC16. The company was founded in 1996 and is headquartered in Edmonton, Canada. |
| URL | http://www.questpharmatech.com |
| Investor Relations URL | N/A |
| HQ State/Province | Alberta |
| Sector | Health Care |
| Industry | Biotechnology |
| Next Earnings Release | N/A |
| Last Earnings Release | N/A |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |